Phase II Trial of Neoadjuvant Bevacizumab, Capecitabine, and Radiotherapy for Locally Advanced Rectal Cancer

摘要: Purpose We designed this Phase II trial to assess the efficacy and safety of addition bevacizumab concurrent neoadjuvant capecitabine-based chemoradiation in locally advanced rectal cancer. Methods Between April 2004 December 2007, 25 patients with clinically staged T3N1 (n = 20) or T3N0 5) cancer received therapy radiotherapy (50.4 Gy 28 fractions over 5.5 weeks), every 2 weeks (3 doses 5 mg/kg), capecitabine (900 mg/m2 orally twice daily only on days radiation), followed by surgical resection a median 7.3 later. Results Procedures included abdominoperineal (APR; 6 patients), proctectomy coloanal anastamosis (8 low anterior (10 local excision (1 patient). Eight (32%) had pathologic complete response, (24%) Conclusions The resulted encouraging response without an increase acute toxicity. impact perineal wound anastamotic healing due requires further study.